Intelligent Bio Solutions Inc., a leading medical technology company serving an emerging, non-invasive brilliant testing solutions, have inked a manufacturing deal with Syrma Johari MedTech Ltd. Syrma is a known well recognized medical device manufacturing and engineering company with decades of experience in scaling and contributing to the creation of its robust Intelligent Fingerprinting Drug Screening Reader. The partnership holds a thread of hope to contribute largely to the long-standing margin improvement.
The collaboration is expected to serve a noteworthy financial and operational benefit for the organisation. The INBS awaits yearly production cost savings of above 40%, responding to a predicted enhancement of an estimated 20% in gross margin in comparison with its existing manufacturing arrangement. Alongside, Syrma’s manufacturing potential is double, triple that of INBS’ current potential. This ranks the company as a smooth contributor to the expected demand as it uplifts the marketing operations.
This collaboration bolsters INBS’ mastermind manufacturing strategy, which focuses on mitigating dependency on a single supplier and creates peak resilience in its robust supply chain. This also expands potential, creating flexibility and promising consistency as the Company plans to secure future demand throughout different regions and intends to enter the U.S. market this year.
Syrma holds an intense and promising track record in the production, engineering and design of ethical medical technology devices. The company is operational in a total of 14 manufacturing locations and serves four innovation and design centers throughout Europe, the United States and India. The center covers a merged plant area of over 1.1 million sq.ft. Syrma holds a certification of ISO 13485, TUV SUD, GMP, MDSAP, and FDA standards, promising quality and best compliance in medical device manufacturing.
The company uplifts the export-centric, vertical unification operating model, allowing the top-class production while generating efficiencies in logistics, sourcing, testing and tooling. Its smart skills in mechanical assembly, functional testing, clean room processes, PCB manufacturing and electronics prove the company’s potential to create INBS’ fingerprint drug-screening reader. The reader to meet a higher standard of expectation while serving cost benefit over time.
Vice President of Global Quality and Operations at Intelligent Bio Solutions, Callistus Sequeira, said, “Collaborating with Syrma Johari is a smart, noteworthy milestone of our business so far. Its worldwide impact, proven track record and manufacturing excellence in regulated medical devices make it an impeccable partner as we bolster and uplift our Drug Screening Reader.”
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
